Yaz

Product Overview

Yaz is a combination hormonal contraceptive containing drospirenone and ethinyl estradiol. Presented in tablet form, it prevents pregnancy through three mechanisms: inhibiting ovulation, thickening cervical mucus to block sperm entry, and thinning the uterine lining to prevent implantation. In addition to contraception, Yaz is approved for treating moderate acne in women and managing symptoms of premenstrual dysphoric disorder (PMDD).

Uses

As an oral contraceptive, Yaz primarily prevents pregnancy by suppressing ovulation and creating physical barriers to conception. It also has therapeutic applications for women experiencing moderate acne vulgaris and PMDD symptoms including emotional instability, irritability, and fluid retention.

How to Use

For optimal effectiveness:
• Take one tablet daily at the same time
• Initiate treatment on day 1 of menstruation for immediate protection
• Follow the sequential numbering on the blister pack
• If a dose is missed, take it immediately upon remembering and continue the regular schedule

How it Works

Yaz’s dual-hormone formula (drospirenone + ethinyl estradiol) mimics natural progesterone and estrogen to:
1. Suppress ovarian follicle development
2. Create a viscous cervical barrier
3. Maintain an endometrial environment unsuitable for implantation

Dosage and Administration

Each 28-tablet cycle consists of:
• 24 active hormone tablets (white)
• 4 inert placebo tablets (green)
Dosing protocol:
1. Daily administration for 24 days (active tablets)
2. 4 days of placebo tablets
3. New pack initiation on day 29 regardless of menstrual status
Note: Backup contraception is recommended during the first treatment week.

Benefits

1. 99% effective with perfect use
2. Dermatological improvement in acne-prone patients
3. PMDD symptom management
4. Menstrual cycle regularization
5. Potential reduction in dysmenorrhea severity

Common Side Effects

Frequently reported transient effects include:
• Gastrointestinal discomfort
• Mammary tenderness
• Cephalalgia
• Intermenstrual spotting
• Emotional lability
These typically resolve within 2-3 cycles. Persistent symptoms warrant medical consultation.

Warnings

Thromboembolic risk considerations:
• Absolute contraindication in smokers >35 years
• Relative contraindication in patients with:
– Thrombophilic disorders
– Uncontrolled hypertension
– Cardiovascular disease history
• Requires risk-benefit assessment in:
– Obese patients (BMI ≥30)
– Prolonged immobilization cases

Storage Information

Storage specifications:
• Temperature: 15-30°C (59-86°F)
• Humidity: <60% • Protection from: - Direct sunlight - Pediatric access - Pet exposure Dispose of expired medication according to local pharmaceutical waste regulations.

Disclaimer:

This information has been medically reviewed for accuracy but does not constitute professional medical advice. The content:
• Is for educational purposes only
• May not reflect all contraindications
• Cannot replace personalized physician consultation
Always consult your healthcare provider regarding:
• Medication interactions
• Individual risk factors
• Therapeutic alternatives
This resource aims to supplement, not substitute, professional medical guidance.